News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Company (LLY) Say CHMP Recommends Approval of BYETTA for Use With Basal Insulin


2/21/2012 8:01:20 AM

Amylin Pharmaceuticals Inc. (AMLN: News ) and Eli Lilly and Co. (LLY: News ) said the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has issued a positive opinion in the European Union or EU for the expanded use of BYETTA as an add-on therapy to basal insulin, with or without metformin and/or Actos, for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The CHMP's decision is now referred for final action to the European Commission, which usually decides on CHMP recommendations within two to three months.

Read at RTT News
Read at Washington Post
Read at PharmaBiz


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES